Alexis Peyroles

Last updated on 2017-09-26T11:05+0300.

About this image

sign

Quotes... Extracted quotes from

Alexis Peyroles souligne : "L'entrée en phase clinique (d'essais sur l'homme, ndlr) est prévue entre fin février et début mars, en France, dans quatre centres hospitaliers. Les résultats sont attendus dans le courant du deuxième trimestre. En parallèle, on va travailler sur une phase 2/3 (dernière étape avant une demande d'homologation, ndlr), et en fonction des évolutions on lancera la commercialisation début 2022. Le financement de la part de Bpifrance couvre pratiquement la première phase d'essais. En parallèle, on discutera avec les autorités et les fondations pour faciliter le financement des phases ultérieures qui ont des coûts beaucoup plus élevés. Il pourrait y avoir un système classique de pré-commandes, comme l'Europe le fait avec un certain nombre de laboratoires" External link

capital-FR Thursday, January 14, 2021 1:34:00 PM EAT

Alexis Peyroles commenté : "va permettre d'accélérer le développement de CoVepiT avec un essai clinique de phase 1/2 qui devrait démarrer début 2021" External link

msn-fr Friday, December 18, 2020 1:16:00 PM EAT

Alexis Peyroles commenté : "va permettre d'accélérer le développement de CoVepiT avec un essai clinique de phase 1/2 qui devrait démarrer début 2021" External link

usinenouvelle Friday, December 18, 2020 12:37:00 PM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

trust2 Tuesday, October 20, 2020 10:14:00 AM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

news-yahoo Monday, October 19, 2020 8:23:00 PM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

thepeninsulaqatar Monday, October 19, 2020 8:00:00 PM EAT

Alexis Peyroles commented : “We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time to eliminate infected cells and avoid developing serious forms. We expect the first preclinical results confirming vaccine protection during this summer. Based on these results, we could launch the clinical phase at the end of the year, provided we have the funding required for this clinical study,” External link

4-traders Thursday, July 16, 2020 8:58:00 AM EAT

Alexis Peyroles commented : "We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time to eliminate infected cells and avoid developing serious forms. We expect the first preclinical results confirming vaccine protection during this summer. Based on these results, we could launch the clinical phase at the end of the year, provided we have the funding required for this clinical study," External link

finanznachrichten-en Thursday, July 16, 2020 8:57:00 AM EAT

Alexis Peyroles précisé : "Compte tenu d'un renforcement significatif de la valeur de Tedopi grâce à ces résultats positifs d'étape 1, nous poursuivons l'exploration d'opportunités de partenariats potentiels pour notre produit" External link

capital-FR Thursday, April 2, 2020 7:40:00 PM EAT

Alexis Peyroles said : "This new patent family, granted in Japan, further expands the patent protection for Tedopi and strengthens our immuno-oncology portfolio. This allowance further validates a specific mechanism of action inducing an early T-lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population, and covering all cancers. Moreover, with more than one million new cancer cases in Japan in 2018*, and a growing oncology drug market in this country and across the world, Tedopi is positioned as a leading asset in multiple oncology indications in a broad population of patients," External link

finanznachrichten-en Tuesday, January 14, 2020 10:14:00 AM EAT

Alexis Peyroles said : “This new patent family, granted in Japan, further expands the patent protection for Tedopi and strengthens our immuno-oncology portfolio. This allowance further validates a specific mechanism of action inducing an early T lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population, and covering all cancers. Moreover, with more than one million new cancer cases in Japan in 2018*, and a growing oncology drug market in this country and across the world, Tedopi is positioned as a leading asset in multiple oncology indications in a broad population of patients,” External link

4-traders Tuesday, January 14, 2020 10:11:00 AM EAT

Alexis Peyroles said : “These encouraging Phase 1 findings, together with the novel and differentiated mechanism of action of OSE-127, the only full-antagonist of IL-7R, provide a firm foundation for further clinical development. These data support the potential of this compound to be a relevant therapy in ulcerative colitis, a chronic inflammatory bowel disease, representing 12.2 per 100,000 people by year* and Sjögren's syndrome, representing 7 per 100,000 people by year**. We look forward to evaluating the product’s efficacy in both indications through two independent Phase 2 studies expected to be initiated in 2020,” External link

4-traders Monday, December 2, 2019 8:48:00 PM EAT

Alexis Peyroles said : “We look forward to combining our companies’ innovative approaches, OSE's neoepitope combination Tedopi® and HalioDx’s pioneering diagnostic applications such as Immunoscore® and Immunosign®, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi® treatment in advanced lung cancer,” External link

businesswire Thursday, November 28, 2019 1:08:00 AM EAT

Alexis Peyroles said : "We look forward to combining our companies' innovative approaches, OSE's neoepitope combination Tedopi and HalioDx's pioneering diagnostic applications such as Immunoscore and Immunosign, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi treatment in advanced lung cancer," External link

finanznachrichten-en Wednesday, November 27, 2019 9:10:00 PM EAT

Alexis Peyroles said : “We look forward to combining our companies’ innovative approaches, OSE's neoepitope combination Tedopi and HalioDx’s pioneering diagnostic applications such as Immunoscore and Immunosign, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi treatment in advanced lung cancer,” External link

4-traders Wednesday, November 27, 2019 8:44:00 PM EAT

Alexis Peyroles said : "The new exploratory data from translational analysis demonstrate that neoepitope combination Tedopi increases the recognition of cancer cells by antigen-specific CD8 T cells with a favorable correlation with patients’ survival. This supports the mechanism of action of Tedopi of increasing the tumor antigen presentation and activation of T-cell priming, leading to an anti-tumoral effect and potentially combatting the main resistance mechanisms to immune checkpoint inhibitors. We are encouraged by these findings and look forward to confirming the correlation between neoepitope response and survival in further translational investigations," External link

4-traders Monday, November 11, 2019 10:40:00 AM EAT

Alexis Peyroles précisé : "Ces conditions sont très favorables pour notre secteur" External link

capital-FR Friday, November 8, 2019 1:01:00 PM EAT

Alexis Peyroles conclu : "Si tout va bien, nous pourrions commercialiser Tedopi en 2022 et toucher ainsi des dizaines de milliers de patients aux Etats-Unis et en Europe" External link

capital-FR Friday, November 8, 2019 1:01:00 PM EAT

Alexis Peyroles said : "We are pleased to announce the licensing of Tedopi® to such a strong partner as CKD, one of the industry leaders in Korea," External link

businesswire Friday, November 8, 2019 7:09:00 AM EAT

Alexis Peyroles commented : “This milestone payment reflects the significant progress made with BI 765063, which is currently in clinical development in collaboration with Boehringer Ingelheim. We view today's announcement as an endorsement of the Company’s partnership and collaboration business model based on innovative products candidates for partnerships and public-private collaborative projects generating significant non-dilutive financing. Since early 2019, in addition to this €5.4 million payment, the Company has received a €15 million in payment from BI upon clinical trial authorization and first patient dosed in the Phase 1. Our business model has allowed OSE to successfully advance its research and clinical development projects without the need for dilutive funding since 2015. With four clinical stage products and financial visibility until end of 2020, OSE is today ideally positioned to become one of the leaders of Immunotherapy in Europe,” External link

businesswire Friday, September 20, 2019 4:17:00 AM EAT

Alexis Peyroles commenté : "Ce paiement d'étape valide les avancées réalisées sur le programme BI 765063, en cours de développement clinique en collaboration avec Boehringer Ingelheim. Ceci illustre la stratégie de la Société axée sur des produits innovants, candidats à des projets collaboratifs public-privé et à des partenariats permettant de générer des financements non dilutifs significatifs" External link

capital-FR Thursday, September 19, 2019 11:47:00 AM EAT

Alexis Peyroles commented : “This milestone payment reflects the significant progress made with BI 765063, which is currently in clinical development in collaboration with Boehringer Ingelheim. We view today's announcement as an endorsement of the Company’s partnership and collaboration business model based on innovative products candidates for partnerships and public-private collaborative projects generating significant non-dilutive financing. Since early 2019, in addition to this €5.4 million payment, the Company has received a €15 million in payment from BI upon clinical trial authorization and first patient dosed in the Phase 1. Our business model has allowed OSE to successfully advance its research and clinical development projects without the need for dilutive funding since 2015. With four clinical stage products and financial visibility until end of 2020, OSE is today ideally positioned to become one of the leaders of Immunotherapy in Europe,” External link

4-traders Wednesday, September 18, 2019 7:38:00 PM EAT

Alexis Peyroles said : “Over the past 18 months, the Company has shown positive turnover and financial results, providing a solid financial position. H1 2019 has seen continued execution of our partnership-focused business model with a number of key milestones achieved on our innovative portfolio in immuno-oncology and autoimmune diseases. We are very pleased with the progress of our products developed in collaboration with Boehringer Ingelheim (BI 765063) and with Servier (OSE-127) which generated an additional €25 million in milestone payments during H1 2019. We are actively pursuing our clinical advances with Tedopi , in Phase 3 in non-small cell lung cancer after failure to previous immune checkpoint inhibitors and in Phase 2 in combination with Opdivo in pancreatic cancer, and continue to explore partnership opportunities for FR104, ready to enter Phase 2 in autoimmune diseases or in transplantation. These achievements, along with multiple ongoing clinical studies aim to demonstrate the potential value of OSE assets in multiple indications, clearly positioning OSE Immunotherapeutics as an emerging leader in the immuno-oncology and autoimmune spaces,” External link

4-traders Thursday, September 5, 2019 7:37:00 PM EAT

Alexis Peyroles commented : "We are very pleased with this first European patent that simultaneously reinforces OSE-703 intellectual property and its position in our portfolio as an IL-7R directed immunotherapy for cancer treatment," External link

finanznachrichten-en Tuesday, September 3, 2019 7:36:00 PM EAT

Alexis Peyroles said ( about Leon Berard ) : “This new collaboration with the Léon Bérard cancer research center, a leader in modern oncology treatments combining translational and immunological research platforms, is focused on an aggressive breast cancer with a strong need for medical innovation. OSE is already strongly involved clinically in the field of myeloid cell-based therapies for cancers,” External link

4-traders Tuesday, July 23, 2019 8:04:00 PM EAT

Alexis Peyroles commented : "We are honored and proud to receive these prestigious prizes, ranking OSE Immunotherapeutics as one of fastest growing European companies involved in innovative projects in immunotherapy. These awards recognize a dramatic growth due to our dynamic business model, based on an original partnership strategy with pharmaceutical leaders supported by an innovative portfolio in immuno-oncology and autoimmune diseases. The awards reward the hard work and expertise of our teams, who continue to show deep commitment and dedication to the continuous growth and strength of the company," External link

finanznachrichten-en Wednesday, July 10, 2019 7:54:00 PM EAT

Alexis Peyroles commented : "OSE Immunotherapeutics has continued to move forward its exciting clinical pipeline in immuno-oncology and autoimmune diseases in 2019. We continue to explore opportunities for our lead product, Tedopi, and for Phase 2-ready FR104 and are very pleased with the progression of partnered drug candidates BI 765063 and OSE-127. These are very interesting products which bring validation to our approach, through the partnerships with Boehringer Ingelheim and Servier, and are already generating important milestone payments for OSE," External link

finanznachrichten-en Wednesday, June 26, 2019 8:51:00 PM EAT

Alexis Peyroles said : "This new IDMC review continues to support the development of Tedopi in NSCLC in patients with unmet medical needs. While checkpoint inhibitors are now considered the standard of care in first- and second-line treatment of advanced NSCLC, many patients still fail to respond or continue to progress on these therapies. Our Phase 3 study with Tedopi is conducted in a patient population with no currently approved therapeutic option, and the clinical need for patients in immune escape after such treatment is strong," External link

4-traders Thursday, June 20, 2019 7:59:00 PM EAT

Alexis Peyroles said : “We are excited to begin first-in-human testing with this novel SIRPα-targeting compound, which we believe has first-in-class potential in the treatment of solid tumors,” External link

businesswire Tuesday, June 18, 2019 9:33:00 AM EAT

Alexis Peyroles said : “The expansion of this new patent family to the United States gives Tedopi, first granted in Japan early 2019, significantly consolidated intellectual property and value. Given the devastating nature of both advanced NSCLC and brain metastatic cancer, there is a great need for new treatment options for patients,” External link

4-traders Tuesday, June 11, 2019 9:07:00 AM EAT

Alexis Peyroles comments : "These new allowances from the CIPO and USPTO reinforce the global patent protection of FR104 and its position as a key product in our autoimmune diseases portfolio. As a Phase 2-ready product with a strong clinical and biological safety profile, and initial signals of clinical efficacy, FR104 is a valuable asset with great potential for further development in a number of autoimmune conditions. We are exploring the best options for continuing the development of our product in autoimmune diseases, including worldwide partnering opportunities," External link

finanznachrichten-en Tuesday, April 9, 2019 8:37:00 PM EAT

Alexis Peyroles said : "We are very excited to begin a new collaboration with an expert team and the CLB, a premier cancer research center. The goal of this partnership is to identify and validate new targets that will help streamline the development of new treatment approaches for cancer, especially in difficult to treat tumors," External link

finanznachrichten-en Tuesday, March 26, 2019 9:27:00 PM EAT

Alexis Peyroles said : “We are very excited to begin a new collaboration with an expert team and the CLB, a premier cancer research center. The goal of this partnership is to identify and validate new targets that will help streamline the development of new treatment approaches for cancer, especially in difficult to treat tumors,” External link

businesswire Tuesday, March 26, 2019 8:34:00 PM EAT

Alexis Peyroles said : "This new patent family, first granted in Japan, is an important step toward further strengthening and expanding our Tedopi immuno-oncology portfolio. The product's use to the treatment of brain metastasis originating from cancers in HLA-A2 positive patients demonstrates the product's therapeutic potential. Tedopi is currently undergoing Phase 3 testing in NSCLC patients following checkpoint inhibitor failure, a patient population with no currently approved therapeutic option, representing an important potential market. In addition, Tedopi is being evaluated in combination with Opdivo, an anti-PD-1 checkpoint inhibitor, in a Phase 2 trial in pancreatic cancer. Tedopi is positioned as a leading asset in multiple oncology indications requiring for novel therapeutic approaches and in patient populations for which a significant medical need exists," External link

finanznachrichten-en Tuesday, January 15, 2019 9:35:00 PM EAT

Alexis Peyroles said : "OSE-127 is highly differentiated by its mechanism of action, which makes it a true antagonist of IL-7R and more likely to deliver therapeutic benefits and we look forward to initiating Phase 1 clinical trial," External link

finanznachrichten-en Monday, December 10, 2018 8:05:00 PM EAT



Key Titles and Phrases Count Lang Last Seen
coo66.67%EN11/15/201615/11/2016
cfo bd33.33%EN05/18/201618/05/2016
Names Lang Count
Alexis PeyrolesEN87.50%
Alexis PeyrolesFR12.50%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Thursday, March 4, 2021

12:38:00 PM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Alexis Peyroles

Last updated on 2017-09-26T11:05+0300.

About this image

sign

Quotes... Extracted quotes from

Alexis Peyroles souligne : "L'entrée en phase clinique (d'essais sur l'homme, ndlr) est prévue entre fin février et début mars, en France, dans quatre centres hospitaliers. Les résultats sont attendus dans le courant du deuxième trimestre. En parallèle, on va travailler sur une phase 2/3 (dernière étape avant une demande d'homologation, ndlr), et en fonction des évolutions on lancera la commercialisation début 2022. Le financement de la part de Bpifrance couvre pratiquement la première phase d'essais. En parallèle, on discutera avec les autorités et les fondations pour faciliter le financement des phases ultérieures qui ont des coûts beaucoup plus élevés. Il pourrait y avoir un système classique de pré-commandes, comme l'Europe le fait avec un certain nombre de laboratoires" External link

capital-FR Thursday, January 14, 2021 1:34:00 PM EAT

Alexis Peyroles commenté : "va permettre d'accélérer le développement de CoVepiT avec un essai clinique de phase 1/2 qui devrait démarrer début 2021" External link

msn-fr Friday, December 18, 2020 1:16:00 PM EAT

Alexis Peyroles commenté : "va permettre d'accélérer le développement de CoVepiT avec un essai clinique de phase 1/2 qui devrait démarrer début 2021" External link

usinenouvelle Friday, December 18, 2020 12:37:00 PM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

trust2 Tuesday, October 20, 2020 10:14:00 AM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

news-yahoo Monday, October 19, 2020 8:23:00 PM EAT

Alexis Peyroles said : "T-cells are like the infantry in our bodies," External link

thepeninsulaqatar Monday, October 19, 2020 8:00:00 PM EAT

Alexis Peyroles commented : “We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time to eliminate infected cells and avoid developing serious forms. We expect the first preclinical results confirming vaccine protection during this summer. Based on these results, we could launch the clinical phase at the end of the year, provided we have the funding required for this clinical study,” External link

4-traders Thursday, July 16, 2020 8:58:00 AM EAT

Alexis Peyroles commented : "We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time to eliminate infected cells and avoid developing serious forms. We expect the first preclinical results confirming vaccine protection during this summer. Based on these results, we could launch the clinical phase at the end of the year, provided we have the funding required for this clinical study," External link

finanznachrichten-en Thursday, July 16, 2020 8:57:00 AM EAT

Alexis Peyroles précisé : "Compte tenu d'un renforcement significatif de la valeur de Tedopi grâce à ces résultats positifs d'étape 1, nous poursuivons l'exploration d'opportunités de partenariats potentiels pour notre produit" External link

capital-FR Thursday, April 2, 2020 7:40:00 PM EAT

Alexis Peyroles said : "This new patent family, granted in Japan, further expands the patent protection for Tedopi and strengthens our immuno-oncology portfolio. This allowance further validates a specific mechanism of action inducing an early T-lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population, and covering all cancers. Moreover, with more than one million new cancer cases in Japan in 2018*, and a growing oncology drug market in this country and across the world, Tedopi is positioned as a leading asset in multiple oncology indications in a broad population of patients," External link

finanznachrichten-en Tuesday, January 14, 2020 10:14:00 AM EAT

Alexis Peyroles said : “This new patent family, granted in Japan, further expands the patent protection for Tedopi and strengthens our immuno-oncology portfolio. This allowance further validates a specific mechanism of action inducing an early T lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population, and covering all cancers. Moreover, with more than one million new cancer cases in Japan in 2018*, and a growing oncology drug market in this country and across the world, Tedopi is positioned as a leading asset in multiple oncology indications in a broad population of patients,” External link

4-traders Tuesday, January 14, 2020 10:11:00 AM EAT

Alexis Peyroles said : “These encouraging Phase 1 findings, together with the novel and differentiated mechanism of action of OSE-127, the only full-antagonist of IL-7R, provide a firm foundation for further clinical development. These data support the potential of this compound to be a relevant therapy in ulcerative colitis, a chronic inflammatory bowel disease, representing 12.2 per 100,000 people by year* and Sjögren's syndrome, representing 7 per 100,000 people by year**. We look forward to evaluating the product’s efficacy in both indications through two independent Phase 2 studies expected to be initiated in 2020,” External link

4-traders Monday, December 2, 2019 8:48:00 PM EAT

Alexis Peyroles said : “We look forward to combining our companies’ innovative approaches, OSE's neoepitope combination Tedopi® and HalioDx’s pioneering diagnostic applications such as Immunoscore® and Immunosign®, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi® treatment in advanced lung cancer,” External link

businesswire Thursday, November 28, 2019 1:08:00 AM EAT

Alexis Peyroles said : "We look forward to combining our companies' innovative approaches, OSE's neoepitope combination Tedopi and HalioDx's pioneering diagnostic applications such as Immunoscore and Immunosign, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi treatment in advanced lung cancer," External link

finanznachrichten-en Wednesday, November 27, 2019 9:10:00 PM EAT

Alexis Peyroles said : “We look forward to combining our companies’ innovative approaches, OSE's neoepitope combination Tedopi and HalioDx’s pioneering diagnostic applications such as Immunoscore and Immunosign, to conduct a translational investigation focused on identifying potential immune biomarkers in NSCLC. Based on the data generated, we aim at defining the profile of responder patients to Tedopi treatment in advanced lung cancer,” External link

4-traders Wednesday, November 27, 2019 8:44:00 PM EAT

Alexis Peyroles said : "The new exploratory data from translational analysis demonstrate that neoepitope combination Tedopi increases the recognition of cancer cells by antigen-specific CD8 T cells with a favorable correlation with patients’ survival. This supports the mechanism of action of Tedopi of increasing the tumor antigen presentation and activation of T-cell priming, leading to an anti-tumoral effect and potentially combatting the main resistance mechanisms to immune checkpoint inhibitors. We are encouraged by these findings and look forward to confirming the correlation between neoepitope response and survival in further translational investigations," External link

4-traders Monday, November 11, 2019 10:40:00 AM EAT

Alexis Peyroles précisé : "Ces conditions sont très favorables pour notre secteur" External link

capital-FR Friday, November 8, 2019 1:01:00 PM EAT

Alexis Peyroles conclu : "Si tout va bien, nous pourrions commercialiser Tedopi en 2022 et toucher ainsi des dizaines de milliers de patients aux Etats-Unis et en Europe" External link

capital-FR Friday, November 8, 2019 1:01:00 PM EAT

Alexis Peyroles said : "We are pleased to announce the licensing of Tedopi® to such a strong partner as CKD, one of the industry leaders in Korea," External link

businesswire Friday, November 8, 2019 7:09:00 AM EAT

Alexis Peyroles commented : “This milestone payment reflects the significant progress made with BI 765063, which is currently in clinical development in collaboration with Boehringer Ingelheim. We view today's announcement as an endorsement of the Company’s partnership and collaboration business model based on innovative products candidates for partnerships and public-private collaborative projects generating significant non-dilutive financing. Since early 2019, in addition to this €5.4 million payment, the Company has received a €15 million in payment from BI upon clinical trial authorization and first patient dosed in the Phase 1. Our business model has allowed OSE to successfully advance its research and clinical development projects without the need for dilutive funding since 2015. With four clinical stage products and financial visibility until end of 2020, OSE is today ideally positioned to become one of the leaders of Immunotherapy in Europe,” External link

businesswire Friday, September 20, 2019 4:17:00 AM EAT

Alexis Peyroles commenté : "Ce paiement d'étape valide les avancées réalisées sur le programme BI 765063, en cours de développement clinique en collaboration avec Boehringer Ingelheim. Ceci illustre la stratégie de la Société axée sur des produits innovants, candidats à des projets collaboratifs public-privé et à des partenariats permettant de générer des financements non dilutifs significatifs" External link

capital-FR Thursday, September 19, 2019 11:47:00 AM EAT

Alexis Peyroles commented : “This milestone payment reflects the significant progress made with BI 765063, which is currently in clinical development in collaboration with Boehringer Ingelheim. We view today's announcement as an endorsement of the Company’s partnership and collaboration business model based on innovative products candidates for partnerships and public-private collaborative projects generating significant non-dilutive financing. Since early 2019, in addition to this €5.4 million payment, the Company has received a €15 million in payment from BI upon clinical trial authorization and first patient dosed in the Phase 1. Our business model has allowed OSE to successfully advance its research and clinical development projects without the need for dilutive funding since 2015. With four clinical stage products and financial visibility until end of 2020, OSE is today ideally positioned to become one of the leaders of Immunotherapy in Europe,” External link

4-traders Wednesday, September 18, 2019 7:38:00 PM EAT

Alexis Peyroles said : “Over the past 18 months, the Company has shown positive turnover and financial results, providing a solid financial position. H1 2019 has seen continued execution of our partnership-focused business model with a number of key milestones achieved on our innovative portfolio in immuno-oncology and autoimmune diseases. We are very pleased with the progress of our products developed in collaboration with Boehringer Ingelheim (BI 765063) and with Servier (OSE-127) which generated an additional €25 million in milestone payments during H1 2019. We are actively pursuing our clinical advances with Tedopi , in Phase 3 in non-small cell lung cancer after failure to previous immune checkpoint inhibitors and in Phase 2 in combination with Opdivo in pancreatic cancer, and continue to explore partnership opportunities for FR104, ready to enter Phase 2 in autoimmune diseases or in transplantation. These achievements, along with multiple ongoing clinical studies aim to demonstrate the potential value of OSE assets in multiple indications, clearly positioning OSE Immunotherapeutics as an emerging leader in the immuno-oncology and autoimmune spaces,” External link

4-traders Thursday, September 5, 2019 7:37:00 PM EAT

Alexis Peyroles commented : "We are very pleased with this first European patent that simultaneously reinforces OSE-703 intellectual property and its position in our portfolio as an IL-7R directed immunotherapy for cancer treatment," External link

finanznachrichten-en Tuesday, September 3, 2019 7:36:00 PM EAT

Alexis Peyroles said ( about Leon Berard ) : “This new collaboration with the Léon Bérard cancer research center, a leader in modern oncology treatments combining translational and immunological research platforms, is focused on an aggressive breast cancer with a strong need for medical innovation. OSE is already strongly involved clinically in the field of myeloid cell-based therapies for cancers,” External link

4-traders Tuesday, July 23, 2019 8:04:00 PM EAT

Alexis Peyroles commented : "We are honored and proud to receive these prestigious prizes, ranking OSE Immunotherapeutics as one of fastest growing European companies involved in innovative projects in immunotherapy. These awards recognize a dramatic growth due to our dynamic business model, based on an original partnership strategy with pharmaceutical leaders supported by an innovative portfolio in immuno-oncology and autoimmune diseases. The awards reward the hard work and expertise of our teams, who continue to show deep commitment and dedication to the continuous growth and strength of the company," External link

finanznachrichten-en Wednesday, July 10, 2019 7:54:00 PM EAT

Alexis Peyroles commented : "OSE Immunotherapeutics has continued to move forward its exciting clinical pipeline in immuno-oncology and autoimmune diseases in 2019. We continue to explore opportunities for our lead product, Tedopi, and for Phase 2-ready FR104 and are very pleased with the progression of partnered drug candidates BI 765063 and OSE-127. These are very interesting products which bring validation to our approach, through the partnerships with Boehringer Ingelheim and Servier, and are already generating important milestone payments for OSE," External link

finanznachrichten-en Wednesday, June 26, 2019 8:51:00 PM EAT

Alexis Peyroles said : "This new IDMC review continues to support the development of Tedopi in NSCLC in patients with unmet medical needs. While checkpoint inhibitors are now considered the standard of care in first- and second-line treatment of advanced NSCLC, many patients still fail to respond or continue to progress on these therapies. Our Phase 3 study with Tedopi is conducted in a patient population with no currently approved therapeutic option, and the clinical need for patients in immune escape after such treatment is strong," External link

4-traders Thursday, June 20, 2019 7:59:00 PM EAT

Alexis Peyroles said : “We are excited to begin first-in-human testing with this novel SIRPα-targeting compound, which we believe has first-in-class potential in the treatment of solid tumors,” External link

businesswire Tuesday, June 18, 2019 9:33:00 AM EAT

Alexis Peyroles said : “The expansion of this new patent family to the United States gives Tedopi, first granted in Japan early 2019, significantly consolidated intellectual property and value. Given the devastating nature of both advanced NSCLC and brain metastatic cancer, there is a great need for new treatment options for patients,” External link

4-traders Tuesday, June 11, 2019 9:07:00 AM EAT

Alexis Peyroles comments : "These new allowances from the CIPO and USPTO reinforce the global patent protection of FR104 and its position as a key product in our autoimmune diseases portfolio. As a Phase 2-ready product with a strong clinical and biological safety profile, and initial signals of clinical efficacy, FR104 is a valuable asset with great potential for further development in a number of autoimmune conditions. We are exploring the best options for continuing the development of our product in autoimmune diseases, including worldwide partnering opportunities," External link

finanznachrichten-en Tuesday, April 9, 2019 8:37:00 PM EAT

Alexis Peyroles said : "We are very excited to begin a new collaboration with an expert team and the CLB, a premier cancer research center. The goal of this partnership is to identify and validate new targets that will help streamline the development of new treatment approaches for cancer, especially in difficult to treat tumors," External link

finanznachrichten-en Tuesday, March 26, 2019 9:27:00 PM EAT

Alexis Peyroles said : “We are very excited to begin a new collaboration with an expert team and the CLB, a premier cancer research center. The goal of this partnership is to identify and validate new targets that will help streamline the development of new treatment approaches for cancer, especially in difficult to treat tumors,” External link

businesswire Tuesday, March 26, 2019 8:34:00 PM EAT

Alexis Peyroles said : "This new patent family, first granted in Japan, is an important step toward further strengthening and expanding our Tedopi immuno-oncology portfolio. The product's use to the treatment of brain metastasis originating from cancers in HLA-A2 positive patients demonstrates the product's therapeutic potential. Tedopi is currently undergoing Phase 3 testing in NSCLC patients following checkpoint inhibitor failure, a patient population with no currently approved therapeutic option, representing an important potential market. In addition, Tedopi is being evaluated in combination with Opdivo, an anti-PD-1 checkpoint inhibitor, in a Phase 2 trial in pancreatic cancer. Tedopi is positioned as a leading asset in multiple oncology indications requiring for novel therapeutic approaches and in patient populations for which a significant medical need exists," External link

finanznachrichten-en Tuesday, January 15, 2019 9:35:00 PM EAT

Alexis Peyroles said : "OSE-127 is highly differentiated by its mechanism of action, which makes it a true antagonist of IL-7R and more likely to deliver therapeutic benefits and we look forward to initiating Phase 1 clinical trial," External link

finanznachrichten-en Monday, December 10, 2018 8:05:00 PM EAT



Key Titles and Phrases Count Lang Last Seen
coo66.67%EN11/15/201615/11/2016
cfo bd33.33%EN05/18/201618/05/2016
Names Lang Count
Alexis PeyrolesEN87.50%
Alexis PeyrolesFR12.50%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Thursday, March 4, 2021

12:38:00 PM EAT


Quotes... Explore Relations


EMM Visual Explorer